ArticleNature2024
Naturally occurring T cell mutations enhance engineered T cell therapies.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
24.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Mapping the clinical landscape of multifunctional CAR T cells: Targets, trends, and synergies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Pooled it
- Disentangling Heterogeneous Molecular Networks for Multi-Omics-Driven Cancer Driver Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Genetically inducible coordinators of cytokine signaling pathways for interrogating T cell motility.bioRxiv : the preprint server for biology · 2026Article
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
- Harnessing macrophage signaling pathways and scalable engineering for next-generation immunotherapies.Signal transduction and targeted therapy · 2026Review
- T cell lymphomas: cancers of aberrant immune synapse signalling.Nature reviews. Immunology · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Discovery of novel tumor-targeting peptide-oncolytic peptide based conjugates (PPCs): A new paradigm for targeted oncolytic-immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8Research square · 2026Article
- Ultra-large targeted DNA integrations in primary human cells.bioRxiv : the preprint server for biology · 2026Article
- Characterization of intestinal immune responses in generalized human and murine lipodystrophy.The Journal of clinical investigation · 2026Article
- BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells.Nature immunology · 2026Article
- Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy.Nature immunology · 2026Article
- De novo identification of the specificities of recurrently identified human T cell receptors.Science advances · 2026Article
- CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency.Nature cancer · 2026Article
- Latent Regulatory Programs Generate Synthetic T Cell States with Enhanced Therapeutic Potential.bioRxiv : the preprint server for biology · 2026Article
- Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy.Nature cancer · 2025Article
- Small-molecule control of CAR T cells.Nature reviews. Chemistry · 2025Review
- CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas.Blood cancer journal · 2025Article
- CAR-T cells in solid tumors: Challenges and breakthroughs.Cell reports. Medicine · 2025Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 4 institutions in 1 country.
Julie Garcia *Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.
Jay Daniels *Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4022-6795
Yujin LeeDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0002-8419-8565
Iowis ZhuDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7852-0987
Kathleen ChengDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Qing LiuDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Daniel GoodmanDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3759-6883
Cassandra BurnettDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.
Calvin LawDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0002-6784-0085
Chloë ThienpontDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0005-2263-1422
Josef AlaviDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.
Camillia AzimiDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0406-5840
Garrett MontgomeryDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-8300-5071
Kole T RoybalDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA. kole.roybal@ucsf.edu.ORCID 0000-0003-3030-7954
Jaehyuk ChoiDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. jaehyuk.choi@northwestern.edu.ORCID 0000-0003-2379-2226
University of California, San Francisco · USNorthwestern University · USGladstone Institutes · USnLIGHT (United States) · US
Funding
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0MCARCINOGENESIS TRAINING PROGRAMT32CA009560 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kathleen Janee Green · 1986 to 2026
$8.4MUser-control and safetyU54CA244438 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2019 to 2022
$7.8MPost Graduate Program in Cutaneous BiologyT32AR060710 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Amy S Paller · 2012 to 2026
$2.4MEngineering the Next-generation of Custom Immune Cell TherapiesDP2CA239143 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROYBAL, KOLE T · 2018 to 2018
$2.4MMechanisms of Lymphomagenesis of Skin Resident Gamma Delta T cellsR01CA260064 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI I. Caroline Le Poole · 2022 to 2026
$2.4MIdentifying Mechanisms Governing T Cell DiversityDP2AI136599 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHOI, JAEHYUK · 2017 to 2017
$2.4MThe Role of ZEB1 Mutations in Cutaneous T Cell LymphomaK08CA191019 · NCI · YALE UNIVERSITY · PI CHOI, JAEHYUK · 2015 to 2019
$760kEngineering Hybrid SynNotch CAR Receptors to Enhance Cell Therapies for CancerF31CA260790 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GARCIA, JULIE MARIE · 2021 to 2023
$108kDissecting mechanisms by which PD1 deletions drive aggressive cutaneous T cell lymphomaF30CA265107 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI DANIELS, JAY · 2021 to 2021
$41kNCI NIH HHS DP2 CA239143NCI NIH HHS F30 CA265107NCI NIH HHS F31 CA260790NCI NIH HHS K08 CA191019NCI NIH HHS R01 CA260064NCI NIH HHS T32 CA009560NCI NIH HHS U54 CA244438NIAID NIH HHS DP2 AI136599NIAID NIH HHS T32 AI007334NIAMS NIH HHS T32 AR060710
Abstract
Adoptive T cell therapies have produced exceptional responses in a subset of patients with cancer. However, therapeutic efficacy can be hindered by poor T cell persistence and function
Indexed as
Evolution, MolecularImmunotherapy, AdoptiveLymphoma, T-Cell, CutaneousMutationT-LymphocytesB-Cell CLL-Lymphoma 10 ProteinCARD Signaling Adaptor ProteinsCD4-Positive T-LymphocytesCytokinesGuanylate CyclaseHumansMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinPhosphatidylinositol 3-KinasesSignal TransductionB-Cell CLL-Lymphoma 10 ProteinBCL10 protein, humanCARD11 protein, humanCARD Signaling Adaptor ProteinsCytokinesGuanylate CyclaseMALT1 protein, humanMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinPhosphatidylinositol 3-KinasesPIK3R3 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.